In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

El Fouly, Amr; Ertle, Judith; El Dorry, Ahmed; Shaker, Mohamed K; Dechêne, Alexander; Abdella, Heba; Mueller, Stefan; Barakat, Eman; Lauenstein, Thomas; Bockisch, Andreas; Gerken, Guido; Schlaak, Joerg F

El Fouly, Amr; Ertle, Judith; El Dorry, Ahmed; Shaker, Mohamed K; Dechêne, Alexander; Abdella, Heba; Mueller, Stefan; Barakat, Eman; Lauenstein, Thomas; Bockisch, Andreas; Gerken, Guido; Schlaak, Joerg F.

Affiliation

El Fouly A; Department of Hepatology and Gastroenterology, University Hospital of Essen, Essen, Germany; Tropical Medicine Dep., Ain Shams University Hospital, Cairo, Egypt; Egyptian Atomic Energy Authority, Cairo, Egypt.

Liver Int ; 35(2): 627-35, 2015 Feb.

Article in En | MEDLINE | ID: mdl-25040497

Subject(s)

Carcinoma, Hepatocellular/drug therapy; Carcinoma, Hepatocellular/radiotherapy; Chemoembolization, Therapeutic/methods; Doxorubicin/therapeutic use; Liver Neoplasms/drug therapy; Liver Neoplasms/radiotherapy; Yttrium/therapeutic use; Chemoembolization, Therapeutic/adverse effects; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Microspheres; Prospective Studies; Survival Rate; Yttrium/adverse effects

Key words

BCLC Stage B; Chemoembolization; Hepatocellular Carcinoma; Intermediate Stage HCC; Radioembolization; TACE; TARE; Yttrium 90

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yttrium / Doxorubicin / Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Liver Int Journal subject: GASTROENTEROLOGIA Year: 2015 Document type: Article Affiliation country: Egypt Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google